itch and itch-related sleep results
Get the relief you’re looking for
Bylvay helped reduce any level of itch (pruritus)
Itch can be one of the most bothersome symptoms of PFIC.
Some people live with itch so long that it feels normal, even though it’s not. For others, itch is frustrating and relentless. Bylvay helped reduce itch whether it was mild or severe.
How itching was measured in the trial
Caregivers recorded scratching scores twice daily on a 5-point scale:
- Less scratching meant an improvement of 1 point or more
- Little or no scratching was a score of 0 or 1 on the scale
Early and lasting reduction of itch with Bylvay
In a clinical trial of 62 people, Bylvay improved caregiver-reported scratching severity as early as week 4 and sustained through 24 weeks in people with PFIC.
Over 24 weeks, little or no scratching was achieved by:
- 35% of patients taking Bylvay 40 mcg/kg/day
- 30% of patients taking Bylvay 120 mcg/kg/day
- 13% of patients taking placebo
By 48 weeks,*
of Bylvay patients achieved little or no scratching
Over 24 weeks, less scratching was experienced by:
- 52% of patients taking Bylvay 40 mcg/kg/day
- 32% of patients taking Bylvay 120 mcg/kg/day
- 11% of patients taking placebo
By 48 weeks,*
of Bylvay patients achieved less scratching
Reduced itch was sustained through 96 weeks
Relief for itch (pruritus) from PFIC is possible with Bylvay
*In the extension trial, all 112 enrolled people received 120 mcg/kg/day of Bylvay.
By 72 weeks, Bylvay patients who had ≥1-point improvement in itch score reported†
